Semaglutide Beats Most GLP-1 Drugs for Weight Loss in Type 2 Diabetes — But Tirzepatide Beats Semaglutide
Meta-analysis of 5,445 patients found semaglutide produced greater weight loss than liraglutide (-6.08 kg difference) and dulaglutide in type 2 diabetes, but tirzepatide outperformed semaglutide by 3.78 kg.
Quick Facts
What This Study Found
Semaglutide showed significantly greater weight loss than liraglutide (mean difference -6.08 kg, 95% CI -8.40 to -3.75) in T2DM patients, while tirzepatide produced significantly greater weight loss than semaglutide (mean difference -3.78 kg, 95% CI -5.52 to -2.04).
Key Numbers
Meta-analysis pooled data from multiple direct comparison trials of semaglutide versus other GLP-1 RAs in T2DM patients.
How They Did This
Systematic review and meta-analysis following PRISMA guidelines. PubMed, Embase, and Cochrane Library were searched for studies comparing semaglutide with other GLP-1 RAs for weight loss in T2DM patients. Nine studies with 5,445 patients (mean age 60, mean follow-up 32.5 weeks) were included. Meta-analysis used SPSS version 29.
Why This Research Matters
With multiple GLP-1 drugs available, patients and doctors need evidence-based guidance on which produces the most weight loss. This meta-analysis provides the clearest head-to-head comparison yet, helping inform treatment choices for the millions of people with type 2 diabetes who need weight management.
The Bigger Picture
The GLP-1 drug landscape is rapidly evolving. This meta-analysis confirms the hierarchy among GLP-1 drugs for weight loss in diabetes: tirzepatide > semaglutide > dulaglutide/liraglutide > exenatide. As even newer multi-agonist drugs (survodutide, retatrutide) enter clinical trials, this ranking will likely continue to evolve. The key message is that not all GLP-1 drugs are equal for weight loss.
What This Study Doesn't Tell Us
Limited to 9 studies — few direct head-to-head trials exist. Mean follow-up of only 32.5 weeks may not capture long-term weight loss differences. The semaglutide vs. dulaglutide comparison didn't reach statistical significance. Different study designs and patient populations across included trials may introduce heterogeneity. Tirzepatide is technically a dual GIP/GLP-1 agonist, not a pure GLP-1 RA.
Questions This Raises
- ?Do the weight loss differences between GLP-1 drugs persist beyond 32 weeks of treatment?
- ?Should the superior weight loss with tirzepatide make it the first-line choice over semaglutide in T2DM patients needing weight management?
- ?How will emerging triple-agonists like retatrutide compare to the current GLP-1 drug hierarchy?
Trust & Context
- Key Stat:
- 6.08 kg more weight loss Semaglutide produced significantly more weight loss than liraglutide in T2DM patients — but tirzepatide outperformed semaglutide by another 3.78 kg
- Evidence Grade:
- Moderate-to-strong evidence from a systematic review and meta-analysis of 9 comparative studies. Limited by the small number of head-to-head trials and relatively short follow-up periods.
- Study Age:
- Published in 2024, providing an up-to-date comparison that includes tirzepatide alongside established GLP-1 drugs.
- Original Title:
- Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.
- Published In:
- Cureus, 16(9), e69008 (2024)
- Authors:
- Wen, Jimmy(4), Nadora, Denise(4), Bernstein, Ethan(3), How-Volkman, Christiane, Truong, Alina, Akhtar, Muzammil, Prakash, Neha A, Puglisi, Jose, Frezza, Eldo
- Database ID:
- RPEP-09522
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Which GLP-1 drug produces the most weight loss for type 2 diabetes?
Based on this meta-analysis, tirzepatide (Mounjaro) produces the most weight loss at 9.7 kg on average — nearly double semaglutide (Ozempic/Wegovy) at 4.81 kg. Among pure GLP-1 drugs (excluding the dual-agonist tirzepatide), semaglutide is the clear leader, significantly outperforming liraglutide (Victoza/Saxenda, 2.81 kg) and exenatide (Byetta/Bydureon, 1.9 kg).
Are the side effects different between these GLP-1 drugs?
The meta-analysis found that all GLP-1 drugs had similar side effect profiles — mostly mild-to-moderate gastrointestinal issues like nausea, vomiting, and diarrhea, which are the most common reasons patients discontinue treatment. There's no strong evidence that one GLP-1 drug has dramatically worse side effects than another, though individual responses vary. The main differentiator is efficacy for weight loss, not safety.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09522APA
Wen, Jimmy; Nadora, Denise; Bernstein, Ethan; How-Volkman, Christiane; Truong, Alina; Akhtar, Muzammil; Prakash, Neha A; Puglisi, Jose; Frezza, Eldo. (2024). Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.. Cureus, 16(9), e69008. https://doi.org/10.7759/cureus.69008
MLA
Wen, Jimmy, et al. "Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.." Cureus, 2024. https://doi.org/10.7759/cureus.69008
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists fo..." RPEP-09522. Retrieved from https://rethinkpeptides.com/research/wen-2024-semaglutide-versus-other-glucagonlike
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.